As the leading organization advocating for reshoring the generic drug industry, CPA’s submission documents how extreme overreliance on foreign pharmaceutical supplies—especially active pharmaceutical ingredients (APIs) and critical injectable drugs from China and India—poses an urgent threat to U.S. national security and patient safety.
This month’s tariff agreements with the United Kingdom and China might end up being the first deal of its kind, and the last. On Friday, President Trump reiterated that the administration could not possibly strike deals with every country, and that tariff announcements would be made over the next two to three weeks.
While CPA recognizes certain positive elements of the deal — including a historic pivot towards prioritizing tariff revenue as well as industrial protection — it remains concerned about dangerous precedents being set by sacrificing domestic production while pursuing foreign market access.
By maintaining the 10% baseline tariff and capping UK auto imports at 100,000 vehicles per year before higher tariffs apply, the administration is demonstrating that trade policy can and should be used to protect and rebuild domestic industry.
The U.S. must not sacrifice the chance to rebuild industrial capacity in exchange for another empty trade promise to import more American goods, as if these promises will actually materialize.
Importers continued to front-run the April ‘Liberation Day’ tariffs in March, sending the overall trade deficit up 14% over February numbers to $140.5 billion for the month, according to the Bureau of Economic Analysis (BEA) on Tuesday.
President Trump’s Executive Order is a bold, necessary move to rebuild America’s pharmaceutical industry and protect our citizens.
Democrats on the Economic Growth, Energy Policy, and Regulatory Affairs Subcommittee—of the House Committee on Oversight and Government Reform—are united against tariffs.
President Trump’s action to close the de minimis loophole for China is a monumental victory for American workers, manufacturers, and national security.
The IPO, widely seen as the first major test of President Trump’s America First Investment Policy (AFIP), directly undermines the President’s February directive to block U.S. investment in companies linked to the Chinese military, human rights abuses, and authoritarian surveillance state.
